Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
| Revenue (TTM) | $24.78B |
| Gross Profit (TTM) | $14.62B |
| EBITDA | $7.93B |
| Operating Margin | 22.90% |
| Return on Equity | 7.08% |
| Return on Assets | 4.19% |
| Revenue/Share (TTM) | $34.87 |
| Book Value | $74.82 |
| Price-to-Book | 2.74 |
| Price-to-Sales (TTM) | 5.82 |
| EV/Revenue | 6.37 |
| EV/EBITDA | 22.31 |
| Quarterly Earnings Growth (YoY) | 9.80% |
| Quarterly Revenue Growth (YoY) | 3.70% |
| Shares Outstanding | $707.77M |
| Float | $630.63M |
| % Insiders | 10.73% |
| % Institutions | 84.45% |
Volatility is currently contracting
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
DHR heads into Q2 earnings with bioprocessing and diagnostics strength, but rising costs and debt could pressure profitability.
Besides Wall Street's top-and-bottom-line estimates for Danaher (DHR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
Investors need to pay close attention to DHR stock based on the movements in the options market lately.
Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott Laboratories (NYSE:ABT | ABT Price Prediction) and Danaher (NYSE:DHR) both closed the books on Q1 2026 with very different stories.
Investors interested in Medical Services stocks are likely familiar with Viatris (VTRS) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?
Danaher's Biotechnology segment posts 7% core revenue growth as bioprocessing demand strengthened, even as weaker product demand created headwinds.
Tap these five stocks, W, DHR, ISRG, BEAT and CSW, with rising P/E ratios to try out an out-of-the-box approach.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DHR and any ticker you trade — then tracks every position and per-strategy win rate.
